Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: A multicenter phase II trial

Journal of Clinical Oncology

Volumn 27, Issue 25, 2009, Pages 4155-4161

  Grossman, Stuart A ^a   Ye, Xiaobu ^a   Chamberlain, Marc ^a   Mikkelsen, Tom ^a   Batchelor, Tracy ^a   Desideri, Serena ^a   Piantadosi, Steven ^a   Fisher, Joy ^a   Fine, Howard A ^a  

^a New Approaches to Brain Tumor Therapy CNS Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TALAMPANEL; TEMOZOLOMIDE; ALKYLATING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; GYKI 53405; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DECUBITUS; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GLIOBLASTOMA; HEMORRHOID; HUMAN; HYPOXIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PYRAMIDAL SIGN; THROMBOCYTOPENIA; VOMITING; ADJUVANT THERAPY; BRAIN TUMOR; DNA METHYLATION; DRUG ANTAGONISM; KAPLAN MEIER METHOD; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SKULL IRRADIATION; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIAZEPINES; BRAIN NEOPLASMS; CRANIAL IRRADIATION; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIERS ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTORS, AMPA; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; UNITED STATES;

EID: 70249128040     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.6895     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Behrens PF, Langemann H, Strohschein R, et al: Extracellular glutamate and other metabolites in and around RG2 rat glioma: An intracerebral microdialysis study. J Neurooncol 47:11-22, 2000
3. Takano T, Lin JH, Arcuino G, et al: Glutamate release promotes growth of malignant gliomas. Nat Med 7:1010-1015, 2001
4. Ye ZC, Sontheimer H: Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 59:4383-4391, 1999
5. Ye ZC, Rothstein JD, Sontheimer H: Compromised glutamate transport in human glioma cells: Reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci 19:10767-10777, 1999
6. de Groot J, Piao Y, Lu L: AMPA receptors promote perivascular glioma invasion via beta1 integrindependent adhesion to the extracellular matrix. Neuro Oncol [epub ahead of print on October 28, 2008]
7. de Groot JF, Piao Y, Lu L, et al: Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol 88:121-133, 2008
8. Ishiuchi S, Tsuzuki K, Yoshida Y, et al: Blockage of ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 8:971-978, 2002
9. Ishiuchi S, Yoshida Y, Sugawara K, et al: Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via akt activation. J Neurosci 27:7987-8001, 2007
10. Emdad L, Sarkar D, Su ZZ, et al: Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 114:155-170, 2007
11. Lee SG, Su ZZ, Emdad L, et al: Astrocyte elevated gene-1 activates cell survival pathways through PI3K-akt signaling. Oncogene 27:1114-1121, 2008
12. Howes JF, Bell C: Talampanel. Neurotherapeutics 4:126-129, 2007
13. Chappell AS, Sander JW, Brodie MJ, et al: A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 58:1680-1682, 2002
14. Piantadosi S: Clinical Trials: A Methodologic Perspective. New York, NY, Wiley, 1997
15. Kaplan EL, Meir P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
16. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
17. Grossman SA, Olson J, Batchelor T, et al: Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol 10:190-198, 2008
18. Kleinberg L, Grossman SA, Carson K, et al: Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: Results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. J Clin Oncol 20:3149-3155, 2002
19. Brem S, Grossman SA, Carson KA, et al: Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol 7:246-253, 2005
20. Laterra JJ, Grossman SA, Carson KA, et al: Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS consortium study. Neuro Oncol 6:15-20, 2004
21. Mikkelsen T, Lush R, Grossman SA, et al: Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme. Invest New Drugs 25:259-263, 2007
22. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
23. Sontheimer H: A role for glutamate in growth and invasion of primary brain tumors. J Neurochem 105:287-295, 2008
24. Sontheimer H: Ion channels and amino acid transporters support the growth and invasion of primary brain tumors. Mol Neurobiol 29:61-71, 2004
25. Yoshida Y, Tsuzuki K, Ishiuchi S, et al: Serumdependence of AMPA receptor-mediated proliferation in glioma cells. Pathol Int 56:262-271, 2006
26. Lyons SA, Chung WJ, Weaver AK, et al: Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res 67:9463-9471, 2007
27. Fu YS, Lin YY, Chou SC, et al: Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: Potential therapeutic application for treatment of gliomas. Neuro Oncol 10:139-152, 2008
28. Lo M, Wang YZ, Gout PW: The x(c)- cystine/ glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 215:593-602, 2008
29. Chung WJ, Lyons SA, Nelson GM, et al: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 25:7101-7110, 2005
30. Robe PA, Martin D, Albert A, et al: A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of sulfasalazine for the treatment of progressing malignant gliomas: Study protocol of [ISRCTN45828668]. BMC Cancer 6:29, 2006
31. Soroceanu L, Manning TJ Jr, Sontheimer H: Modulation of glioma cell migration and invasion using cl(-) and K(+) ion channel blockers. J Neurosci 19:5942-5954, 1999
32. Rzeski W, Turski L, Ikonomidou C: Glutamate antagonists limit tumor growth. Proc Natl Acad Sci U S A 98:6372-6377, 2001
33. Shigeri Y, Seal RP, Shimamoto K: Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev 45:250-265, 2004